Physician profile
Ellen Doyle
NPI 1942872056
$8,742.64
in general payments reported to CMS, 2019-2025
33 companies · $4,262 in 2025
The $4,262 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.62 · 2022: $716 · 2023: $2,017 · 2024: $1,655 · 2025: $4,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,933.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,020.20 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $877.06 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $684.99 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $577.61 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Lilly USA, LLC | $408.87 | 2021-2025 | Omvoh |
| Qol Medical, LLC | $398.93 | 2022-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $396.92 | 2023-2025 | |
| Ardelyx, INC. | $296.10 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $210.24 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $205.37 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $184.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $180.38 | 2023-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $141.26 | 2024-2025 | Iqirvo |
| Daiichi Sankyo INC. | $139.71 | 2022-2024 | Injectafer |
| Aimmune Therapeutics, INC. | $131.48 | 2024-2025 | Zenpep |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $119.67 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $115.84 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $112.76 | 2023-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $104.34 | 2023-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $81.34 | 2022-2024 | Dificid |
| Novo Nordisk INC | $61.78 | 2025 | Wegovy |
| Amgen INC. | $57.27 | 2023 | Avsola, Amjevita |
| Celgene Corporation | $47.15 | 2023-2024 | Zeposia |
| Mallinckrodt Hospital Products INC. | $25.90 | 2025 | Terlivaz |
| Janssen Scientific Affairs, LLC | $25.30 | 2024 | Tremfya |
| Enterra Medical, INC. | $24.05 | 2025 | |
| Alnylam Pharmaceuticals INC. | $23.80 | 2025 | Givlaari |
| Mylan Institutional INC. | $17.53 | 2023 | Hulio |
| Eisai INC. | $16.97 | 2022 | |
| Axonics, INC. | $16.26 | 2022 | |
| Medtronic, INC. | $15.21 | 2024 | Interstim |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.93 | 2022 | |
| Genentech USA, INC. | $8.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.